肿瘤浸润淋巴细胞和低剂量rhIL-2综合治疗进展期肿瘤的初步研究  

Tumor-infiltration Lymphocytes in Combination with Low-dose Interleukin-2 in the Treatment of 20 Advanced Cancers

作　　者：姚德茂[1] 潘承恩[1] 王一理[2] 司履生[2] 孟绍青[1] 

机构地区：[1]西安医科大学第一附属医院外科,西安市710061 [2]西安医科大学免疫病理研究室

出　　处：《中国肿瘤临床》1997年第5期339-342,共4页Chinese Journal of Clinical Oncology

基　　金：陕西省卫生厅科研基金

摘　　要：对20例经手术切除的进展期肿瘤患者用活化的自身肿瘤浸润淋巴细胞（TIL）和重组人白细胞介素－2（rhIL－2）治疗，并检测治疗前后细胞免疫变化。患者的PBL对同种异体相同组织学类型靶细胞的细胞毒性明显升高（P＜0．05），而对无关靶细胞的细胞毒性无明显变化（P＞0．05）；外周血淋巴细胞产生IL－2的能力均有明显的提高，从12．3U／ml到19．8U／ml（P＜0．01）；对植物血凝素（PHA）皮试反应性明显增强，反应直径从8．6mm升高到13．5mm（P＜0．01）。TIL输注过程中，11例有一过性寒战、发热（T＜38℃），其中6例伴轻度恶心、呕吐。结果提示：单次输注TIL和小剂量rhIL－2综合治疗后，可明显提高进展期肿瘤患者的细胞免疫功能，而无严重毒副作用，可能成为进展期肿瘤术后重要的辅助治疗方法。Twenty cases of advanced cancers of stomach,liver,bladder were treated with activated auto-tumor-infiltrating lymphocytes (TIL) isolated from the patients themselves and supplemented by reconbinant interleukin-2 (rIL-2). Cellular immune response was assayed before and after TIL infusion. The results revealed that cytotoxicity was much elevated (P<0. 05). There was no significant change in cytotoxicity to histologically unrelated target cell lines (P>0. 05). Serum IL-2 level was elevated markedly (12. 3U/ml to 19. 8U/ml, P<0. 01 ). PHA skin test turned positive and the skin reaction lesion enlarged (PHA: 8, 6 mm to 13. 5 mm,P<0. 01 ). Eleven patients had transient chill and fever (T<38℃); and mild nausea and vomiting were seen in 6 of them during the TIL infusion. All these results indicate that TIL plus low-dose rIL-2 are able to improve cellular immunity in patients with advanced cancer without side-effect. It may play an important role in preventing recurrence and metastasis.

关 键 词：肿瘤浸润 淋巴细胞 RHIL-2 肿瘤 综合疗法 

分 类 号：R730.51[医药卫生—肿瘤]